Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anthera Pharmaceuticals IncANTH · Entity 163677 | Director | January 05, 2018 | January 09, 2018 |
| CymaBay Therapeutics, Inc.CBAY · Entity 92768 | Director | January 26, 2021 | January 28, 2021 |
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Director | May 31, 2022 | June 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anthera Pharmaceuticals Inc
Report date January 05, 2018 · Filed January 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2028-01-05 | Direct | 84,705 |
Reported balance
After 2018-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-05 · Grant · Acquired 84,705 · Balance 84,705 F1: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2028-01-05 | Direct | 84,705 |
Reported balance
After 2018-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-05 · Grant · Acquired 84,705 · Balance 84,705 F2: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017.
F2: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018.
CymaBay Therapeutics, Inc.
Report date January 26, 2021 · Filed January 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.78 · Expires 2031-01-25 | Direct | 32,000 |
Reported balance
After 2021-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-26 · Grant · Acquired 32,000 · Balance 32,000 F1: The option vests as to 1/12 of the underlying shares monthly from January 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the underlying shares monthly from January 1, 2021.
Milestone Pharmaceuticals Inc.
Report date May 31, 2022 · Filed June 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 81,780 |
Ending reported balance
After 2022-05-31 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2022-05-31 · Exercise / conversion · Acquired 8,016 · Balance 8,016 Row 2 · 2022-05-31 · Exercise / conversion · Acquired 45,072 · Balance 53,088 Row 3 · 2022-05-31 · Exercise / conversion · Acquired 22,870 · Balance 75,958 Row 4 · 2022-05-31 · Exercise / conversion · Acquired 822 · Balance 76,780 Row 5 · 2022-05-31 · Purchase · Acquired 5,000 · Balance 81,780 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2025-08-26 | Direct | 0 |
Reported balance
After 2022-05-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-31 · Exercise / conversion · Disposed 8,016 · Balance 0 F1: Fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.54 · Expires 2027-07-21 | Direct | 0 |
Reported balance
After 2022-05-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-31 · Exercise / conversion · Disposed 45,072 · Balance 0 F1: Fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.54 · Expires 2028-10-15 | Direct | 2,659 |
Reported balance
After 2022-05-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-31 · Exercise / conversion · Disposed 22,870 · Balance 2,659 F2: Twenty-five percent (25%) of the shares subject to the option shall vest on October 15, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.66 · Expires 2028-11-20 | Direct | 117 |
Reported balance
After 2022-05-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-31 · Exercise / conversion · Disposed 822 · Balance 117 F3: Twenty-five percent (25%) of the shares subject to the option shall vest on November 21, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested and exercisable.
F2: Twenty-five percent (25%) of the shares subject to the option shall vest on October 15, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
F3: Twenty-five percent (25%) of the shares subject to the option shall vest on November 21, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2022 Filed Jun 1, 2022 21:32 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionStock Option (right to buy) · Derivative | 822 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-22-033336 · doc4.xml · derivative · entry 9 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117 Underlying: Common Shares · 822 shares Expires 2028-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on November 21, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:32 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionStock Option (right to buy) · Derivative | 22,870 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001209191-22-033336 · doc4.xml · derivative · entry 8 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,659 Underlying: Common Shares · 22,870 shares Expires 2028-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on October 15, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:32 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionStock Option (right to buy) · Derivative | 45,072 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001209191-22-033336 · doc4.xml · derivative · entry 7 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,072 shares Expires 2027-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:32 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionStock Option (right to buy) · Derivative | 8,016 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-22-033336 · doc4.xml · derivative · entry 6 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,016 shares Expires 2025-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:32 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | PurchaseCommon Shares | 5,000 | $5.60 | $28,000.00 |
DisclosureSEC source: 0001209191-22-033336 · doc4.xml · nonDerivative · entry 5 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,780 Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:32 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionCommon Shares | 822 | $2.66 | $2,186.52 |
DisclosureSEC source: 0001209191-22-033336 · doc4.xml · nonDerivative · entry 4 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:32 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionCommon Shares | 22,870 | $1.54 | $35,219.80 |
DisclosureSEC source: 0001209191-22-033336 · doc4.xml · nonDerivative · entry 3 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:32 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionCommon Shares | 45,072 | $1.54 | $69,410.88 |
DisclosureSEC source: 0001209191-22-033336 · doc4.xml · nonDerivative · entry 2 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:32 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionCommon Shares | 8,016 | $1.12 | $8,977.92 |
DisclosureSEC source: 0001209191-22-033336 · doc4.xml · nonDerivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2021 Filed Jul 29, 2021 17:40 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0001209191-21-048575 · doc4.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 14, 2021, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 15:00 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $5.78 | $0.00 |
DisclosureSEC source: 0001333277-21-000025 · edgar.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2021. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 19:10 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001209191-20-035120 · doc4.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2030-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the 12 months commencing July 5, 2020, provided that the shares subject to this option shall vest in full on the date of Issuer's 2021 annual meeting of shareholders, subject to recipient continuing to provide service to the Issuer through such vesting date. Read SEC document |
| May 15, 2020 Filed May 19, 2020 17:22 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (Right to Buy) · Derivative | 49,245 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-20-030600 · doc4.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,245 Underlying: Common Stock · 49,245 shares Expires 2030-05-14 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on January 31, 2020, subject to the Reporting Person's continuous service to the Issuer as of each such date. Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 18:41 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $17.78 | $0.00 |
DisclosureSEC source: 0001209191-19-056626 · doc4.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Shares · 4,000 shares Expires 2029-11-12 F1 · derivative.exercise_date: This option will vest in equal monthly installments, beginning on December 12, 2019, over a period of three years, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:22 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 27,705 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001333277-19-000023 · edgar.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,705 Underlying: Common Stock · 27,705 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:45 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001333277-18-000031 · edgar.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly beginning January 1, 2018. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 06:35 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | GrantStock Option (right to buy) · Derivative | 84,705 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001214659-18-000292 · marketforms-40677.xml · derivative · entry 2 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,705 Underlying: Common Stock · 84,705 shares Expires 2028-01-05 F2 · derivative.exercise_date: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 06:35 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | GrantStock Option (right to buy) · Derivative | 84,705 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001214659-18-000292 · marketforms-40677.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,705 Underlying: Common Stock · 84,705 shares Expires 2028-01-05 F1 · derivative.exercise_date: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 11:27 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001209191-17-053912 · doc4.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2017-09-21 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date. The option allows for early exercise by the Reporting Person. Read SEC document |
| September 07, 2017 Filed Sep 7, 2017 18:56 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | PurchaseCommon Stock | 5,000 | $1.34 | $6,700.00 |
DisclosureSEC source: 0001214659-17-005551 · marketforms-39597.xml · nonDerivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 16,793 F1 · kind: The Reporting Person acquired the shares in the open market and through the 2005 Truex Family Trust u/d/t April 20, 2005. Shares have been adjusted to reflect the issuer's 1-for-8 reverse stock split effectuated on April 28, 2017. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 14:32 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001042074-17-000012 · primary_doc.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017. Read SEC document |
| May 19, 2017 Filed May 19, 2017 20:00 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | OtherStock option (right to buy) · Derivative | 84,376 | $0.00 Strike: $39.04 | $0.00 |
DisclosureSEC source: 0001214659-17-003496 · marketforms-38868.xml · derivative · entry 2 TRUEX PAUL F · CIK 0001120362 · Director · Executive Chaiman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,376 shares Expires 2023-05-17 F2 · kind: On May 19, 2017, the reporting person and the Company agreed to cancel a stock option to purchase 84,376 shares of common stock dated May 17, 2013 (the "option"), which option was previously reported on a Form 4 filed with the SEC on May 21, 2013. This option was to vest annually over four years beginning March 25, 2013 (the Vesting Start Date). The Option would have completely vested on the fourth anniversary of the Vesting Start Date and would expire on May 17, 2023. F2 · derivative.exercise_date: On May 19, 2017, the reporting person and the Company agreed to cancel a stock option to purchase 84,376 shares of common stock dated May 17, 2013 (the "option"), which option was previously reported on a Form 4 filed with the SEC on May 21, 2013. This option was to vest annually over four years beginning March 25, 2013 (the Vesting Start Date). The Option would have completely vested on the fourth anniversary of the Vesting Start Date and would expire on May 17, 2023. Read SEC document |
| May 19, 2017 Filed May 19, 2017 20:00 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | OtherStock option (right to buy) · Derivative | 1,369 | $0.00 Strike: $96.64 | $0.00 |
DisclosureSEC source: 0001214659-17-003496 · marketforms-38868.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director · Executive Chaiman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,369 shares Expires 2019-02-18 F1 · kind: On May 19, 2017, the reporting person and the Company agreed to cancel an outstanding stock option to purchase 1,369 shares of common stock dated February 18, 2009 (the "option"), which option was previously reported on a Form 4 filed with the SEC on February 23, 2010. 50% of the options were to vest monthly over four years beginning August 12, 2008 (the Vesting Start Date) and 50% of the options vested upon successful completion of milestones determined by the Board. The options were fully vested on August 12, 2012. The Option would expire on Feburary 18, 2019. F1 · derivative.exercise_date: On May 19, 2017, the reporting person and the Company agreed to cancel an outstanding stock option to purchase 1,369 shares of common stock dated February 18, 2009 (the "option"), which option was previously reported on a Form 4 filed with the SEC on February 23, 2010. 50% of the options were to vest monthly over four years beginning August 12, 2008 (the Vesting Start Date) and 50% of the options vested upon successful completion of milestones determined by the Board. The options were fully vested on August 12, 2012. The Option would expire on Feburary 18, 2019. Read SEC document |
| January 19, 2017 Filed Jan 23, 2017 18:31 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001179110-17-001192 · edgar.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The option vests in three annual installments from the vesting start date of January 19, 2017. Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 21:05 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | OtherStock option (right to buy) · Derivative | 180,000 | $0.00 Strike: $9.48 | $0.00 |
DisclosureSEC source: 0001214659-16-015226 · marketforms-37311.xml · derivative · entry 2 TRUEX PAUL F · CIK 0001120362 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 180,000 shares Expires 2025-09-17 F2 · kind: On December 2, 2016, the Reporting Person and the Company agreed to cancel a stock option to purchase 180,000 shares of common stock dated September 17, 2015 (the "Option"), which Option was previously reported on a Form 4 filed with the SEC on September 18, 2015. This Option was to vest monthly over four years beginning September 17, 2015 (the "Vesting Start Date"). The Option would have completely vested on the fourth anniversary of the Vesting Start Date and would have expired on September 17, 2025. F2 · derivative.exercise_date: On December 2, 2016, the Reporting Person and the Company agreed to cancel a stock option to purchase 180,000 shares of common stock dated September 17, 2015 (the "Option"), which Option was previously reported on a Form 4 filed with the SEC on September 18, 2015. This Option was to vest monthly over four years beginning September 17, 2015 (the "Vesting Start Date"). The Option would have completely vested on the fourth anniversary of the Vesting Start Date and would have expired on September 17, 2025. Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 21:05 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | OtherStock option (right to buy) · Derivative | 170,000 | $0.00 Strike: $9.48 | $0.00 |
DisclosureSEC source: 0001214659-16-015226 · marketforms-37311.xml · derivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,000 shares Expires 2025-09-17 F1 · kind: On December 2, 2016, the Reporting Person and the Company agreed to cancel a stock option to purchase 170,000 shares of common stock dated September 17, 2015 (the "Option"), which Option was previously reported on a Form 4 filed with the SEC on September 18, 2015. The Option was to vest monthly over four years beginning December 30, 2014 (the "Vesting Start Date"). The Option would have completely vested on the fourth anniversary of the Vesting Start Date and would have expired on September 17, 2025. F1 · derivative.exercise_date: On December 2, 2016, the Reporting Person and the Company agreed to cancel a stock option to purchase 170,000 shares of common stock dated September 17, 2015 (the "Option"), which Option was previously reported on a Form 4 filed with the SEC on September 18, 2015. The Option was to vest monthly over four years beginning December 30, 2014 (the "Vesting Start Date"). The Option would have completely vested on the fourth anniversary of the Vesting Start Date and would have expired on September 17, 2025. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 19:29 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | GiftCommon stock | 5,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-16-013774 · marketforms-36324.xml · nonDerivative · entry 3 TRUEX PAUL F · CIK 0001120362 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 94,345 F1 · kind: On September 20, 2016, the reporting person transferred 5,008 shares to the 2005 Truex Family Trust u/d/t April 20, 2005 Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 19:29 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | GiftCommon stock | 5,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-16-013774 · marketforms-36324.xml · nonDerivative · entry 2 TRUEX PAUL F · CIK 0001120362 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On September 20, 2016, the reporting person transferred 5,008 shares to the 2005 Truex Family Trust u/d/t April 20, 2005 Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 19:29 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | Exercise / conversionCommon stock | 5,008 | $2.08 | $10,416.64 |
DisclosureSEC source: 0001214659-16-013774 · marketforms-36324.xml · nonDerivative · entry 1 TRUEX PAUL F · CIK 0001120362 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2007 Filed Sep 22, 2016 19:29 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | Exercise / conversionStock Option (right to buy) · Derivative | 5,008 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001214659-16-013774 · marketforms-36324.xml · derivative · entry 4 TRUEX PAUL F · CIK 0001120362 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,845 Underlying: Common Stock · 5,008 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments from the vesting commencement date of October 3, 2005. This stock option was fully exercisable on October 3, 2009. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.